Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Sponsor: Innate Pharma

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06088654

Patient View

This international, open-label Phase 1/2 study evaluates IPH6501's safety and tolerability in patients with advanced CD20+ B-cell NHL. Phase 1 involves dose escalation to find the MTD and dose assessment for RP2D. Phase 2 focuses on dose expansion in selected cohorts. The intervention involves administering IPH6501 to determine its optimal dosing and safety profile.

Patient Parameters

Program Overview

This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.

Description

In Phase 1 - Dose finding, patients with advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin lymphoma (NHL) will be enrolled. The dose finding part will include 2 sub-parts: Dose escalation will determine the Maximum Tolerated Dose (MTD) or the highest tested dose, Dose assessment will determine RP2D.

In Phase 2 - Dose expansion, one or more cohorts will be selected with patients with subtypes of advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin lymphoma.

Eligibility Criteria

Main Inclusion criteria

  • Patients with advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin's lymphoma (NHL) including the following types defined by WHO 2016: Diffuse Large B Cell Lymphoma (DLBCL); high grade; thymic; Follicular Lymphoma (FL); Mantle cell lymphoma (MCL); Marginal zone lymphoma (MZL)
  • Relapsed, progressive and/or refractory disease without established alternative therapy
  • Must have received at least 2 prior systemic therapies including at a minimum anti-CD20 antibody therapy (e.g., rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Adequate organ and hematological function
  • Able to provide a fresh biopsy from a safely accessible site (or historical biopsy), per investigator determination.

Main Exclusion Criteria

  • Patients with another invasive malignancy in the last 2 years
  • Prior chemotherapy, immunotherapy or other anti-cancer therapy within less than 4 weeks before study drug administration.
  • Autologous stem cell transplant or treatment with CAR-T (Chimeric Antigen Receptor T-Cell) cell therapy within 100 days prior to first dose of study drug
  • Subjects with brain or subdural metastases are not eligible, nor those with history of central nervous system (CNS) lymphoma
  • Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease.
  • Known history of infection with human immunodeficiency virus (HIV) or hepatitis B or C
  • Major surgery within 4 weeks before the first dose of study drug
  • Comorbidities including diabetes, cardiovascular diseases, immunodeficiencies/autoimmune condition
  • Pregnant / breastfeeding woman

Get This Program In Your Inbox

You can sign up and apply your patients for this program.